Profiel
David L.
Snitman was the founder of Array BioPharma, Inc. (founded in 1998) where he held the title of Executive Vice President-Business Development in 2015.
He previously worked as an Associate Director-New Products & Technology at Amgen, Inc. and as a Director at BaroFold, Inc. Dr. Snitman received his undergraduate degree from Northeastern University and his doctorate from The University of Colorado.
Eerdere bekende functies van David L. Snitman
| Bedrijven | Functie | Einde |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Founder | 30-06-2015 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | - |
BaroFold, Inc.
 BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Director/Board Member | - |
Opleiding van David L. Snitman
| Northeastern University | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
BaroFold, Inc.
BaroFold, Inc. Pharmaceuticals: MajorHealth Technology BaroFold, Inc. develops and commercializes protein therapeutics. Its services include protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression. The company was founded by Matthew Seefeldt, Matthew Brewer, John F. Carpenter, Ted Randolph, Timothy C. Rodell, and Lyndal K. Hesterberg in 2009 and is headquartered in Aurora, CO. | Health Technology |
